Boston, Massachusetts, September 27, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced encouraging new data of non-carrier-added (n.c.a.) 177 Lu-edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The findings were presented in two posters at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, held from September